strength ahead anoth hcv drop
updat forecast estim dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim dec
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
gilead gener stellar profit margin hiv hcv
portfolio requir small salesforc inexpens
manufactur think firm portfolio pipelin support
wide moat gilead need hcv market stabil strong
continu innov hiv solid pipelin data smart futur
acquisit return growth
gilead tenofovir molecul -- viread truvada older
single-tablet regimen -- histor form heart firm
afford less like miss dose develop
drug resist need make one co-payment older
combo pill atripla first replac gilead complera
stribild better safeti profil newest combo
pill -- replac tenofovir taf -- reduc bone kidney safeti
issu see rapid uptak gilead biggest competit
threat hiv glaxo triumeq saw rapid growth glaxo
 test novel combin also bypass gilead
drug howev gilead genvoya odefsey descovi
launch push patent protect late
boost market share
sovaldi harvoni combin sovaldi ledipasvir
launch peak billion sale
howev launch all-or regimen late
merck launch zepati lead steep discount
shrink market demand fall sharpli expect gilead
current launch eight-week regimen mavyret
share billion-plu market long term
gilead build pipelin outsid hiv hcv need
acquisit like kite car-t therapi axi-cel see
strong growth gilead first cancer drug zydelig launch
limit safeti concern optimist
galapago collabor lead nash program selonsertib
also phase open multi-billion-dollar opportun
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strength ahead anoth hcv drop oct
third quarter patient demand fall new
competit abbvi mavyret emerg
transit newest hiv regimen move swiftli
maintain fair valu estim
make signific chang valuat
alreadi incorpor acquisit kite newli
approv car-t cell therapi aggress lymphoma
yescarta think gilead diversifi hiv hepat
franchis strengthen oncolog portfolio emerg
potenti immunolog nonalcohol steatohepat
expect continu hiv strength gilead launch new
taf regimen signific step-up hcv price
pressur hcv contribut china remain
uncertain gilead third-quart revenu fell
declin hepat revenu partli counter
hiv hepat revenu although
fundament growth hiv/hbv closer
account one-tim reserv payment gilead aim
toward high end previou product sale guidanc
due hiv out-performance hcv under-perform
slightli rais estim full year taf-
base regimen genvoya top hiv product new
patient europ gilead latest
bictegravir-bas triplet approv februari
 europ expect see
larger hcv hit fourth quarter
mavyret gilead still negoti contract
end sovaldi also recent approv china
gilead hope begin gain reimburs
eventu expand china portfolio includ harvoni
epclusa hepat vemlidi hepat price
still uncertain howev sever drug also
enter market china isnt current materi driver
model
oncolog nash two biggest driver
valuat beyond hiv hcv yescarta launch
price despit smaller refractori
patient popul think global sale easili exceed
billion assum usag eventu expand
second-lin diffus larg b-cell lymphoma set later
line therapi gilead also work advanc nash
pipelin recent solid data inhibitor
show impact liver fat fibrosi proof-of-concept
data combin either selonsertib alreadi phase
monotherapi enrol complet
fxr agonist potenti safer option
intercept oca like preclin data
indic selonsertib provid greater
efficaci combin overal includ
billion probability-adjust sale gilead model
nash
valuat growth profit oct
follow close acquisit kite pharma
maintain fair valu estim gilead
includ billion sale axi-cel
eventu approach billion usag expand
second-lin dlbcl therapi form blood cancer
assum billion gilead hcv sale
think lower patient demand
key headwind follow addit price
headwind next-gener product
expect new product either significantli
reduc gilead patient share forc price patient
price harvoni eight-week regimen
result see gilead hcv revenu billion
today declin around
overal think gilead hiv/hbv franchis peak
billion gener competit lead
roughli averag annual headwind begin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gilead portfolio divers hiv focu
expand exposur hepat cancer market
still think firm warrant medium uncertainti
rate owe volatil hepat market demand
price
bullish scenario expect gilead achiev stronger
convers newer hiv product stronger
hepat price power scenario assum hiv
franchis sale peak billion follow
midteen declin face gener competit
also assum less aggress rebat hepat
 market bull-cas scenario result billion
hepat sale gilead also use slightli
higher earnings-growth rate stage ii
model result fair valu estim per
pessimist scenario assum complera
stribild next-gener taf-bas regimen like
genvoya unabl gain signific share hiv
market lack perceiv efficaci safeti
conveni benefit compar older regimen
glaxo doublet regimen hiv franchis sale peak
billion fall single-digit rate
rapid drop owe sever pressur
also assum addit price competit
hepat market rebat eventu rise
 market result billion
hepat sale gilead also use
earnings-growth rate stage ii model
patent protect newer hiv regimen gilead
assum taf-bas combin
regimen genvoya descovi odefsey help off-set
declin gilead could see mid-single-digit patient
loss annual begin continu
view stribild complera gener strong long-term
competit taf-bas regimen particularli outsid
forecast averag annual sale declin
non-gaap earn declin sovaldi
lower tax rate led oper margin
shrink revenu think margin
declin roughli assum
cost-cut help off-set margin pressur
assum cost capit gilead rate
systemat risk surround gilead share
averag assum cost equiti align
capit cost assumpt return equiti investor
like demand long run also assum
pre-tax cost debt reflect normal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
continu domin hepat market
enough ensur strong return next coupl
decad gilead expertis infecti diseas
single-pil formul part research
develop strategi see one strongest
intang asset support firm wide moat
gilead moat form leadership posit
treatment hiv three patent product form
backbon today treatment regimen despit
numer competitor compani establish
lead market share spectacular profit
conveni effect safe treatment gilead serv
treat hiv patient unit state
manag done excel job maxim sale
tenofovir molecul present viread
truvada atripla complera stribild said key
patent begin
europ
provid
suffici differenti reimburs key
market put pressur hiv franchis begin
expir
howev think firm shown translat
extens understand drug discoveri
develop process hiv new therapeut area
allow achiev wide-moat statu despit initi
critic high price gilead paid pharmasset
earli billion acquisit gave gilead
valuabl hepat drug industri also
demonstr firm abil recogn potenti
uniqu natur sovaldi safeti efficaci profil
compar toxic nucleotid analog think
firm experi anoth nucleotid analog tenofovir
key ingredi gilead hiv combin regimen
probabl contribut recognit sovaldi valu
earli stage develop
molecul sovaldi harvoni redefin gilead
powerhous broader infecti diseas market
gilead lead way all-or treatment
hepat market gilead multi-billion-dollar
product think low resist potenti
pan-genotyp efficaci gilead regimen allow
firm retain close global hcv market
long run despit competit merck
product platform reflect grow record recogn
potenti infecti diseas discoveri
foundat hiv drug tenofovir deal brought right
emtricitabin anoth ingredi gilead
combin regimen elvitegravir integras inhibitor
stribild sovaldi gilead oncolog pipelin also
grow advanc receiv boost
recent acquisit kite includ car-t cell therapi
axi-cel think firm smart acquisit
potenti futur combin regimen hematolog
oncolog immunolog nash diversifi
firm strengthen intang asset howev
think gilead hiv-rel patent exposur price
volum headwind hepat market prevent
moat expand
see grow evid firm acquisit
strategi could serv well oncolog immunolog
follow sever year smaller acquisit
idelalisib via calistoga launch safeti risk
limit usag later line therapi howev
oncolog drug safer dose zydelig combin
therapi still test sever potenti
immunolog indic well axi-cel acquir kite
pharma octob like launch diffus
larg b-cell lymphoma think gilead histori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
demand declin rel steadili beyond
smart clinic trial design market expertis could
boost launch speed long-term potenti kite
portfolio addit acquisit arresto nimbu
apollo well licens deal phenex given
gilead sever differ mechan treat nash
potenti combin
gilead product biolog firm
vulner gener version mani older hiv
product within five year howev newer hiv regimen
complera stribild saw strong launch genvoya
improv kidney bone safeti profil led fastest
hiv combin pill sale ramp help
differenti drug gener version gilead
truvada atripla stribild genvoya gilead
retain virtual econom behind hiv sale
rather share partner complera
johnson johnson atripla bristol-my squibb
benefit firm return invest capit
gilead also face strong competit hiv continu
see gilead best-posit field approv
glaxo integras inhibitor tivicay combin tablet
triumeq epzicom/tivicay led gilead market share
declin glaxo gilead appear
gain share hiv player merck bristol
lack combin pill expect gilead
novel nonboost integras inhibitor launch
glaxo dual-combo pill phase test
continu domin market
gilead pipelin continu sale hiv beyond first
wave patent expir need counter declin
hcv tough year sale
declin bring larger hit demand
falter launch next-gener product
beyond assum annual headwind hcv
sale remain forecast period price patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ogilead market sever single-tablet regimen hiv
firm next-gener product better
long-term safeti profil led genvoya boost
ogilead hiv franchis see first import
patent expir firm
need convert patient newer product like
genvoya avoid signific hit sale
oguidelin aim
improv diagnosi
treatment rate new prophylaxi use provid
strong tailwind growth hiv
owith approv sovaldi harvoni gilead
market leader all-or hepat treatment
none gilead competitor nucleotid
analog make billion acquisit
opric pressur reduc willing pay
conveni could weigh gilead growth atripla
becom formid gener competitor
gilead newer hiv product compet
hepat regimen give pbm abil
ohcv patient demand plummet visibl
long-term demand price low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
gilead held billion cash billion debt
end gilead continu rais debt
rel low rate assum blend interest rate
includ billion debt term loan
support octob acquisit kite pharma
gilead use cash fund aggress share repurchas
billion rel new dividend gilead
hiv hcv busi also gener stellar cash flow
despit declin hcv sale gilead easili gener
around billion free cash flow annual
expect gilead use cash futur
acquisit particularli tax reform allow one-tim
repatri oversea cash note share
repurchas dial back significantli fund
dividend growth acquisit
increas competit price pressur hiv
hepat market risk gilead global price
pressur consolid pharmacy-benefit manag
could reduc gilead abil charg price premium
new drug extend patent protect gilead newest
hiv product perceiv offer improv safeti
efficaci versu older hiv product larg portion
sale foundat could risk patent gilead
top market hiv product expir firm
need see signific switch newer product like
genvoya counter neg impact gener
competitor estim gilead
purchas higher rebat sale
implement escal overal healthcar cost
tight budget could lead continu elev price
pressur europ gilead also paid
signific premium acquir myogen failur
darusentan put even pressur letairi make
deal accret said billion pharmasset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
acquisit foundat gilead hcv franchis
allow gilead gener billion hcv
revenu howev gilead hcv busi declin
steepli competit allow pharmaci benefit
manag like express script aggress negoti
price gilead appear gain vast major
contract access patient sacrif price
hiv express script could exclud stribild genvoya
safe effect
competit -- like gilead atripla complera -- lose
formulari
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
assign gilead exemplari mark stewardship base
moat-build invest strategi good alloc
capit superior board
independ
qualif gilead made sever acquisit
collabor deal year support
infecti diseas portfolio exampl acquisit
triangl brought emtriva critic compon
truvada firm single-tablet hiv regimen
outsid gilead therapeut area focu acquisit
cv also wise invest angina
drug ranexa grow strongli addit billion
bet pharmasset -- hepat drug sovaldi --
excel use capit earli judg
billion acquisit kite pharma current
assum deal neutral long-term roic upsid
possibl axi-cel price exce expect
john martin step role ceo march
role board chang chairman
execut chairman appreci martin still
voic gilead strategi given tenur
ceo background antivir chemistri bristol john
milligan promot ceo also
join board milligan martin insid
gilead board independ
skill set includ expertis public polici infecti
diseas global health initi like
manag reward progress rather
earn per share gilead decis boost share
repurchas smart one view share
trade fair valu estim much
past three year see blood cancer immunolog
key area futur growth gilead
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gilead deepen blood cancer commit pivot
cell therapi kite maintain gilead fve
gilead acquir kite pharma all-cash deal worth
billion per share continu view
gilead share slightli under-valued fair valu
estim per share diversifi gilead
portfolio price gilead paid look neutral long-
term roic assum approv strong price kite
cell therapi axicabtagen ciloleucel axi-cel biggest
indic second- third-lin dlbcl think
gilead wide moat remain stabl plan rais
kite fair valu estim match offer price
deal expect close fourth quarter
gilead oncolog portfolio focus blood cancer
deal zydelig inhibitor alreadi approv
leukemia lymphoma seriou side effect
limit use advanc patient kite deal
move gilead new territori kite cell therapi
focu axi-cel receiv food drug
administr approv treatment patient
refractori case certain form aggress non-hodgkin
lymphoma includ dlbcl novemb kite
readi axi-cel commerci launch expect
gilead histori smart clinic trial design market
expertis could boost launch speed long-term
potenti kite portfolio forecast axi-cel sale
billion driven larg uptak
roughli third patient second-lin later dlbcl
billion entir axi-cel franchis
includ area mantl cell lymphoma
plan incorpor addit valu kite
enter develop year
market alreadi quit competit therapi like
discuss juli blood-cancer-focus
healthcar observ steadi blood cancer pipelin
creat opportun build exist moat dlbcl
analysi begin page roch rituxan current
domin roughli billion dlbcl market
treatment landscap pois remain dynam
subset nhl among car-t therapi dlbcl kite axi-
cel data durabl respons strong
manufactur track record compar novarti
approv octob relapsed/refractori
file dlbcl year juno enter
pivot trial dlbcl pfizer/cellecti use
off-the-shelf allogen car-t cell enter
develop one risk broader uptak cost
current model net price per dose axi-cel
actual price could substanti higher well
north roughli cost rituxan dlbcl
standard first-lin treatment notabl less
roughli cost stem cell transplant common
anoth risk complex cell therapi axi-cel
combin therapi rituxan novel oral drug
immuno-oncolog antibodi better patient segment
molecular diagnost could improv cure rate
first-lin option leav fewer patient would requir
cell therapi treatment roughli patient
subtyp dlbcl oral therapi like js
imbruvica phoenix data expect celgen
revlimid robust data expect could approv
combin rituxan chemotherapi earli
addit molecular diagnost like impact
treatment expect roch move
forward late-stag trial inhibitor venclexta
alreadi approv treatment certain form cll
elev roughli half dlbcl patient
antibodi keytruda opdivo poor data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
non-hodgkin lymphoma monotherapi data rituxan
promis data btk inhibitor
next year could also present opportun
drug gain share expect roch continu
invest heavili blood cancer come year
progress new therapi like firm bispecif
antibodi target could prove safer
effect rituxan dlbcl final progress
antibodi design could allow effect off-the-shelf
treatment target therapi
early-stag develop hand axi-cel could
also becom part combin regimen
trial combin axi-cel roch tecentriq
specif highlight call
under-valued ahead new hcv competit jul
gilead rais guidanc stronger-than-
expect hcv treatment rate first half
year slightli boost hcv revenu
forecast full year roughli billion midpoint
updat guidanc howev isnt enough
significantli chang fair valu estim still
see gilead share slightli under-valued
pois launch competit hcv regimen fall
glaxo two-drug hiv regimen produc phase data
end year gilead like see top-lin
growth least absenc large-scal
acquisit maintain wide moat rate given
gilead domin hiv hcv strong return
invest capit next sever year even
hcv campaign improv diagnosi sinc
fall appear stabil demand similar
effort way europ gilead expect
patient treat hcv
prior guidanc
manag caution still expect declin
second half overal sale gilead pangenotyp epclusa
regimen week grow sale sovaldi
previous favor foundat genotyp patient
shrink harvoni still genotyp standard
often use eight week appear see slower
approv gilead vosevi
treatment patient fail prior regimen
like drive signific uptak geographi
vosevi anticip approv eight-week regimen
europ broader group patient despit fail
show noninferior epclusa could make
competit new regimen
expect approv like august europ
creat addit price volum pressur
expect eight-week regimen launch price pariti
gilead eight-week harvoni regimen would
signific discount epclusa price
hiv recent phase bictegravir data allow gilead
launch new regimen still model
signific price pressur glaxo launch two-drug
regimen gilead compet
first-gener combin regimen
continu expect rapid uptak taf-bas regimen
genvoya descovi odefsey partli counter
declin europ second half year patent
expir older product viread truvada atripla recent
detail studi compar gilead new single-tablet
regimen contain integras inhibitor bictegravir
regimen base glaxo integras inhibitor tivicay
show noninferior efficaci although glaxo nrti
foundat contain triumeq appear
caus side effect gilead taf-bas backbon
compet two-drug regimen like launch
time frame glaxo file
tivicay/edur combin patient alreadi suppress
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
tripl combo therapi launch regimen
expect data glaxo regimen
end year treatment-na patient said
still doubt long-term safeti efficaci
regimen
investor still wait gilead make key
strateg decis focu area outsid hiv hcv
potenti large-scal acquisit also see
opportun upsid fair valu estim
dont think gilead pipelin recent valuat wild
card could includ posit data later year
gastric cancer posit data cur hiv drug
candid phase data earli nash
program outsid phase drug selonsertib
phase data earli filgotinib
ulcer coliti lead next-gener jak
inhibitor current includ billion nash
revenu model year signific upsid
trial continu progress plan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
